Effects of pilocarpine on the cardiovascular and respiratory system
Main Article Content
Keywords
pilocarpine, xerostomia, heart rate, respiratory rate, perfusion
Abstract
Introduction: The main drug used for the treatment of xerostomia is pilocarpine. Objective: To evaluate the cardiopulmonary repercussions of intraperitoneal administration of pilocarpine (2 mg/kg) in Wistar rats. Method: Animals were divided into two groups: control group (SAL) and pilocarpine treated group (PILO), and evaluated by means of spirometry, electrocardiography and analysis of blood perfusion in peripheral musculature. The data were evaluated in the following situations: 1) Basal and 2) Stimulation: Saline or Pilocarpine. Results: The PILO group had a statistical decrease in heart rate and respiratory rate, but did not alter in pulmonary ventilation and peripheral blood perfusion compared to the SAL group. Conclusion: Treatment with pilocarpine at a low dose to induce salivary secretion promoted bradypnea and bradycardia in rats, without repercussion on pulmonary ventilation and peripheral blood perfusion.
References
2. Chojnowska S, Baran T, Wilinska I, Sienicka P, Cabaj-Wiater I, Knas M. Human saliva as a diagnostic material. Adv Med Sci. 2018;63(1):185-91.
3. Saleh J, Figueiredo MA, Cherubini K, Salum FG. Salivary hypofunction: an update on aetiology, diagnosis and therapeutics. Arch Oral Biol. 2015;60(2):242-55.
4. Garrett JR. The proper role of nerves in salivary secretion: a review. J Dent Res. 1987;66(2):387-97.
5. Ferguson M. Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol. 1993;75(2):186-91.
6. Dowd FJ. Cholinergic Agonists and Muscarinic Receptor Antagonists. Pharmacology and Therapeutics for Dentistry2017. p. 82-97.
7. Han P, Suarez-Durall P, Mulligan R. Dry mouth: a critical topic for older adult patients. J Prosthodont Res. 2015;59(1):6-19.
8. Paganini M, Dezan CC, Bichaco TR, de Andrade FB, Neto AC, Fernandes KB. Dental caries status and salivary properties of asthmatic children and adolescents. Int J Paediatr Dent. 2011;21(3):185-91.
9. Quock RL. Xerostomia: current streams of investigation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(1):53-60.
10. Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs. 1995;49(1):143-55.
11. Lehnen AM, Leguisamo NM, Casali KR, Schaan BD. Progressive cardiovascular autonomic dysfunction in rats with evolving metabolic syndrome. Auton Neurosci. 2013;176(1-2):64-9.
12. Turner MD. Hyposalivation and Xerostomia: Etiology, Complications, and Medical Management. Dent Clin North Am. 2016;60(2):435-43.
13. Guggenheimer J, Moore PA. Xerostomia. The Journal of the American Dental Association. 2003;134(1):61-9.
14. Millsop JW, Wang EA, Fazel N. Etiology, evaluation, and management of xerostomia. Clin Dermatol. 2017;35(5):468-76.
15. Radvansky LJ, Pace MB, Siddiqui A. Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. Am J Health Syst Pharm. 2013;70(12):1025-32.
16. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjogren's syndrome. Clin Immunol. 2001;101(3):249-63.
17. Villa A, Connell CL, Abati S. Diagnosis and management of xerostomia and hyposalivation. Ther Clin Risk Manag. 2015;11:45-51.
18. Tangsucharit P, Takatori S, Zamami Y, Goda M, Pakdeechote P, Kawasaki H, et al. Muscarinic acetylcholine receptor M1 and M3 subtypes mediate acetylcholine-induced endothelium-independent vasodilatation in rat mesenteric arteries. J Pharmacol Sci. 2016;130(1):24-32.
19. Brown SM, Koarai A, Sturton RG, Nicholson AG, Barnes PJ, Donnelly LE. A role for M(2) and M(3) muscarinic receptors in the contraction of rat and human small airways. Eur J Pharmacol. 2013;702(1-3):109-15.
20. Romero AC, Bergamaschi CT, de Souza DN, Nogueira FN. Salivary Alterations in Rats with Experimental Chronic Kidney Disease. PLoS One. 2016;11(2):e0148742.